OasisLMS

CME Available - No Technologist Credit

This self‑assessment focuses on neuromuscular junction disorders across the lifespan, including autoimmune myasthenia gravis (AChR and MuSK), congenital myasthenic syndromes, Lambert‑Eaton myasthenic syndrome, infant botulism, and transient neonatal myasthenia. Through case‑based multiple‑choice questions, learners will practice identifying characteristic clinical signs, understanding disease mechanisms and treatment targets, choosing and interpreting electrodiagnostic and serologic tests, and making safe, evidence‑based therapeutic decisions in common and challenging neuromuscular junction scenarios. 

The Neuromuscular Junction Disorders Self-Assessment (SA) is an excellent study guide for maintenance of certification or preparing for board exams. The American Board of Psychiatry and Neurology (ABPN) and the American Board of Physical Medicine and Rehabilitation (ABPMR) have reviewed and approved this product as part of a comprehensive lifelong learning program, which is mandated by the American Board of Medical Specialties (ABMS) as a necessary component of continuous certificaiton.

OBJECTIVES:
The objectives of this exam are to: 1) recognize key clinical, electrophysiologic, and pharmacologic features of autoimmune and congenital myasthenic syndromes, Lambert‑Eaton myasthenic syndrome, and neuromuscular junction involvement in congenital myopathies; 2) select appropriate diagnostic tests and interpret characteristic findings in neuromuscular junction disorders, including single‑fiber EMG jitter, repetitive nerve stimulation patterns, and relevant laboratory evaluations; 3) formulate initial, condition‑specific treatment strategies for myasthenia gravis, Lambert‑Eaton myasthenic syndrome, infant botulism, transient neonatal myasthenia, and drug‑related neuromuscular junction complications.


ACCREDITATION STATEMENT
The AANEM is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

DISCLOSURE INFORMATION :
Dr. Shruti Raja is a consultant for OVID Therapeutics, Inc. Conflicts have been mitigated according ot ACCME standards. All authors, planners, and reviewers of this activity had nothing to disclose.

CREDIT DESIGNATION :
The AANEM designates this enduring material for a maximum of 4.0 AMA PRA Category 1 Credits ^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

FORMAT: Online Exam

Miguel Chuquilin, MD; Partha Ghosh, MD; Shruti Raja, MD; Dora Leung, MD.